Biomarkers.

Background: Subjective cognitive decline (SCD) is thought to be a preclinical stage of Alzheimer's disease (AD), associated with faster disease progression and with imaging and cerebrospinal fluid biomarkers. However, it is unclear whether and how the degree of SCD correlates with plasma biomarkers. To address this, we investigated the association of plasma biomarkers of AD with established validated measures of SCD.

Biomarkers.

Background: We evaluated whether baseline differences existed in various plasma Alzheimer's disease (AD) biomarkers in cognitively normal participants racialized as Black or White.

Method: This cross-sectional study included 203 (n=83 non-Hispanic Black [NHB] and n=120 non-Hispanic White [NHW]) cognitively unimpaired older adults from the NYU Alzheimer's Disease Research Center. Of the 203, 115 (39NHB, 76 NHW) had tau-PET (PI-2620/MK-6240) data; 195 (85 NHB, 110 NHW) had amyloid-PET (florbetaben); 98 (39 NHB, 59 NHW) had plasma Aβ40 and Ab42 data, 93 (37 NHB, 56 NHW) had data for total tau, 135 (55 NHB, 80 NHW) had neurofilament light (NfL) and glial fibrillary protein (GFAP) data and 139 (57 NHB, 82 NHW) had pTau181 data.

Alzheimer's Imaging Consortium.

Background: We evaluated whether baseline differences existed in various plasma Alzheimer's disease (AD) biomarkers in cognitively normal participants racialized as Black or White.

Method: This cross-sectional study included 203 (n = 83 non-Hispanic Black [NHB] and n = 120 non-Hispanic White [NHW]) cognitively unimpaired older adults from the NYU Alzheimer's Disease Research Center. Of the 203, 115 (39NHB, 76 NHW) had tau-PET (PI-2620/MK-6240) data; 195 (85 NHB, 110 NHW) had amyloid-PET (florbetaben); 98 (39 NHB, 59 NHW) had plasma Aß40 and Ab42 data, 93 (37 NHB, 56 NHW) had data for total tau, 135 (55 NHB, 80 NHW) had neurofilament light (NfL) and glial fibrillary protein (GFAP) data and 139 (57 NHB, 82 NHW) had pTau181 data.

Alzheimer's Imaging Consortium.

Background: Subjective cognitive decline (SCD) is a preclinical stage of Alzheimer's disease (AD), with correlations to cerebral amyloid and tau and accelerated cognitive decline. Studies have also revealed an association between sleep fragmentation and such AD biomarkers and cognitive decline, suggesting that cognitive function should be monitored in individuals experiencing excessive sleepiness. It is unclear if and how sleep dysfunction relates to SCD apart from AD biomarkers, as well as symptoms related to SCD and sleep dysfunction, such as depression.

Cyclosporine A Delays the Terminal Disease Stage in the Tfam KO Mitochondrial Myopathy Mouse Model Without Improving Mitochondrial Energy Production.

Introduction And Aims: Mitochondrial myopathies are rare genetic disorders for which no effective treatment exists. We previously showed that the pharmacological cyclophilin inhibitor cyclosporine A (CsA) extends the lifespan of fast-twitch skeletal muscle-specific mitochondrial transcription factor A knockout (Tfam KO) mice, lacking the ability to transcribe mitochondrial DNA and displaying lethal mitochondrial myopathy. Our present aim was to assess whether the positive effect of CsA was associated with improved in vivo mitochondrial energy production.